A Randomised, Double-blind, Placebo-controlled, Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of MT-2990 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
Price : $35 *
At a glance
- Drugs MT-2990 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 22 May 2017 New trial record